banner_advertise_728

Lamisil versus clotrimazole in the treatment of vulvovaginal candidiasis.

Authors:
Ali Zarei Mahmoudabadi
Ali Zarei Mahmoudabadi
School of Medicine
Iran
Eskandar Moghimipour
Eskandar Moghimipour
Ahvaz Jundishapur University of Medical Sciences
Iran
Zahra Seifi
Zahra Seifi
Ahvaz Jundishapur University of Medical Sciences
Iran

Iran J Microbiol 2013 Mar;5(1):86-90

Department of Medical Mycology, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran ; Infectious Diseases and Tropical Medicine Centre, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.

Background And Objectives: Vaginal candidiasis is a common disease in women during their lifetime and occurs in diabetes patients, during pregnancy and oral contraceptives users. Although several antifungals are routinely used for treatment; however, vaginal candidiasis is a challenge for patients and gynecologists. The aim of the present study was to evaluate terbinafine (Lamisil) on Candida vaginitis versus clotrimazole.

Materials And Methods: In the present study women suspected to have vulvovaginal candidiasis were sampled and disease confirmed using direct smear and culture examination from vaginal discharge. Then, patients were randomly divided into two groups, the first group (32 cases) was treated with clotrimazole and the next (25 cases) with Lamisil. All patients were followed-up to three weeks of treatment and therapeutic effects of both antifungal were compared.

Results: Our results shows that 12 (37.5%) patients were completely treated with clotrimazole during two weeks and, 6(18.8%) patients did not respond to drugs and were refereed for fluconazole therapy. Fourteen (43.8%) patients showed moderate response and clotrimazole therapy was extended for one more week. When Lamisil was administrated, 19 (76.0%) patients were completely treated with Lamisil in two weeks, and 1 (4.0%) of the patients did not respond to the drug and was refereed for fluconazole therapy. Five (20.0%) of our patients showed moderate response and Lamisil therapy was extended for one more week.

Conclusion: Our results show that vaginal cream, 1% Lamisil, could be suggested as a first-line treatment in vulvovaginal candidiasis.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3577561PMC
banner_advertise_728
March 2013
203 Reads

Publication Analysis

Top Keywords

vulvovaginal candidiasis
12
patients
10
vaginal candidiasis
8
patients respond
8
patients moderate
8
completely treated
8
treatment vulvovaginal
8
therapy extended
8
fluconazole therapy
8
moderate response
8
refereed fluconazole
8
patients completely
8
treated clotrimazole
8
lamisil
7
candidiasis
5
culture examination
4
week lamisil
4
examination vaginal
4
extended week
4
randomly divided
4

Similar Publications